Boeing reported Q3 2026 revenue of $24.2B, up 4% YoY but slightly below the $24.37B consensus, with a GAAP loss per share of ($0.26) and a core loss per share of ($0.34), both worse than the consensus estimate of ($0.20). The Commercial Airplanes segment saw revenue decline 3% YoY to $10.7B due to…
Three small asset managers added LDOS positions in Q3, while Robeco Institutional Asset Management trimmed a large stake. The net dollar flow is negative ($20.3M outflow) due to Robeco's sizable reduction, but the buyer count (3) exceeds sellers (1). The cluster is mixed: small active managers accumulating vs. a large institutional seller trimming.
T3 Defense Inc. filed an 8-K announcing it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $10 million. The deficiency was caused by liability-classified warrants from a $20 million February 2026 private placement, which drove stockholders' equity from $42.5 million at March 31, 2026 to a deficit of $19.7 million at June 30, 2026. As of September 30, 2026, approximately 96% of the warrants were exercised, eliminating the non-cash liability and bringing pro forma stockholders' equity to approximately $99.9 million, well above the listing requirement. Nasdaq has not yet confirmed compliance, and the company remains subject to monitoring.
The SEC declared effective T3 Defense Inc.'s S-1 registration (File No. 333-298752) on October 22, 2026, enabling the company to proceed with its IPO. This follows the filing of Amendment No. 2 to the S-1 on October 20, which added exhibits. The effectiveness clears the way for the company to begin trading on Nasdaq under the ticker DFNS, with pricing expected imminently. However, the company is in severe financial distress with a going concern qualification, negative equity, and a Nasdaq minimum equity deficiency notice, making this a high-risk IPO.
Lockheed Martin reported Q3 2026 EPS of $7.97, missing consensus estimates of $8.56 by 6.9%, while revenue of $20.7B also missed the $22.48B consensus. The company raised its full-year 2026 guidance for sales, EPS, and free cash flow for the second consecutive quarter, and reported a record backlog of $292B. The EPS miss is partially explained by lower F-35 deliveries (43 vs 46 YoY) and an F-35 Lot 20 contract risk disclosure, but the raised guidance and record backlog provide a positive counterweight.
T3 Defense Inc. filed Amendment No. 2 to its Form S-3 shelf registration statement, registering up to $250,000,000 in common stock, preferred stock, debt securities, warrants, subscription rights, and units. The filing is a routine shelf registration that provides the company with flexibility to raise capital over time, but it signals potential future dilution.
Three active asset managers accumulated $154.1M in new PLTR positions during Q3 2026, while two trimmed $28.5M. The buying was concentrated in mid-sized additions and a doubling by Td Waterhouse Canada, but the sellers reduced larger positions.
T3 Defense Inc. filed Amendment No. 2 to its S-1 registration statement on October 20, 2026, solely to add exhibits (including a legal opinion from McDermott Will & Schulte LLP) and update the exhibit list. The filing relates to the resale of up to 10,000,000 shares of common stock by a selling stockholder (Esousa Group Holdings LLC) pursuant to a September 19, 2025 Securities Purchase Agreement. This is a procedural step in the registration process with no new financial or operational disclosures.
RTX reported Q3 2026 results with strong double-digit sales and earnings growth, and raised its full-year 2026 guidance for adjusted sales, adjusted EPS, and free cash flow for the second consecutive quarter. The company posted record backlog of $340 billion and benefited from IEEPA cost recovery, though operating cash flow declined YoY due to prior-year timing.
RTX reported Q3 2026 adjusted EPS of $2.26, beating the $1.78 consensus by 27%, and sales of $24.97B, above the $24.11B estimate. The company raised its full-year 2026 guidance for adjusted sales, adjusted EPS, and free cash flow, driven by double-digit organic growth across all three segments and a record $340B backlog.
Northrop Grumman reported Q3 2026 sales of $11.1B (+7% YoY) and diluted EPS of $7.89, slightly below the consensus estimate of $7.93. The company raised its 2026 MTM-adjusted EPS guidance midpoint by $0.70 to $29.55 and its segment operating income midpoint by $65M, while maintaining sales and free cash flow guidance. Backlog reached a record $109.6B, up 15% YTD, driven by strong awards including Sentinel and restricted programs.
Four Palantir insiders, including C-suite executive Taylor Ryan D., sold a total of $5.30M in shares over a one-week window. The sales are open-market and not flagged as 10b5-1 plan transactions, representing approximately 0.16% of the company's market cap — a modest but notable cluster. No insider buying offsets the selling, suggesting a cautious internal view near current price levels.
Kochav Defense Acquisition Corp. is seeking shareholder approval to extend its business combination deadline from November 29, 2026 to November 29, 2027, without the Sponsor depositing additional funds into the trust account. The Sponsor has declined to make the $5.06 million in extension payments it was obligated to under the original charter. If the extension is not approved and no deal closes by the current deadline, the SPAC will liquidate, returning approximately $10.53 per share to public holders, and all founder shares, private placement units, and rights will expire worthless.
Three institutional asset managers accumulated $160.8M in RTX during Q3 2026, led by Assenagon Asset Management doubling its position to $253.6M and TD Waterhouse Canada more than doubling to $56.1M. One small seller, Davenport & Co, fully exited a $21.9M position.
Three Palantir insiders, including a senior executive and two directors, sold a total of $4.83M in open-market sales over a one-week period. The sales are modest relative to the company's market cap and may reflect routine portfolio diversification, but the concentration of selling by multiple insiders warrants attention.
Rocket Lab announced that the first launch of its Neutron rocket, previously expected in 2026, is now anticipated to shift into 2027. The company cited ongoing development and process improvements as reasons for the delay. No financial figures or revised cost estimates were provided.
Two Palantir insiders sold a total of $3.87M in stock over a one-week window, including a $3.62M sale by a named executive (Taylor Ryan D.) and a $254K sale by a director. The sales are open-market transactions without any indicated 10b5-1 plan, representing approximately 0.1% of Palantir's market cap. While the dollar amount is modest relative to the company's size, the absence of a plan and the involvement of a senior executive warrant attention.
Institutional activity in KTOS during Q2 2026 was mixed: a small group of active quant and asset managers (Millennium, Susquehanna, Jane Street) more than doubled their positions, adding ~$91M in net buying, while a much larger wave of mega-passive funds (Geode, Fidelity, Northern Trust, T. Rowe Price) trimmed or nearly exited, collectively selling $377M. The net effect was heavy selling by passive index rebalancers, partially offset by conviction buying from active managers.
A mixed institutional cluster for Palantir (PLTR) in Q2 2026: 77 buyers accumulated $1.57B in net new positions, while 47 sellers reduced holdings by $440.6M. The buying was dominated by mega-passive funds (JPMorgan, Goldman Sachs, UBS) and two quant/asset managers (Millennium, Susquehanna) that more than quadrupled their stakes, but notable active sellers like T. Rowe Price, Capital Group, and two quant funds (Bridgewater, Point72) exited or trimmed significantly. The net $1.13B inflow is large in absolute terms but heavily passive, and the 45-day reporting lag means positions may have already been adjusted.
Barclays initiated coverage on Boeing Co (BA) with an Overweight rating and a $300 price target, implying 55.7% upside from the current $192.72. The call is bullish and above the consensus mean target of $273.42. Barclays has a 53% accuracy rate on 7,205 calls with a 3.9% average return, placing it in the middle tier among firms covering BA. The consensus is heavily bullish: 32 of 37 analysts rate BA Buy or Strong Buy, 5 Hold, 0 Sell. The $300 PT is just below the high target of $305 and above the median of $272.50. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days, though EPS estimates for the current quarter have been revised down slightly. Institutional activity is mixed: Capital Research Global Investors doubled its stake, while UBS trimmed and Renaissance Technologies nearly exited. Short interest is elevated at 55.1% of float, suggesting significant bearish positioning. The next earnings report is on October 27, 2026, within 30 days, adding a timing catalyst. The bottom line: Barclays' initiation at Overweight with a top-decile PT reinforces the bullish consensus, but high short interest and mixed institutional flows create a contested setup.
Goldman Sachs upgraded Palantir Technologies Inc. (PLTR) from Neutral to Buy on October 8, 2026, setting a price target of $230, implying 21.4% upside from the current price of $189.40. The firm has a 60% accuracy rate on 5 calls for PLTR with an average return of 49.3%, placing it above average among covering analysts. Consensus on PLTR is heavily bullish: 28 of 39 analysts rate it Buy (72%), 9 Hold (23%), and 2 Sell (5%). The mean price target is $195.57, median $205.05, with a high of $255 and low of $80; Goldman's $230 target sits above both the mean and median. In the past 30 days, there has been 1 upgrade and 0 downgrades, while EPS estimates for the current quarter have seen 22 upward revisions and 0 downward revisions over 30 days. Insider selling has been notable, with multiple sales by EVP Moore Alexander D. totaling over $1.9 million in September, though these may be routine. Institutional activity is mixed: JPMorgan added 36.8% and Goldman Sachs Group added 29.5%, while Capital Research trimmed 30.3% and T. Rowe Price trimmed 40.2%. Short interest stands at 56.0% of float, indicating elevated bearish positioning. The next earnings report is due November 2, 2026, within 30 days, adding a timing catalyst. Overall, the upgrade from a high-return firm with strong upward estimate momentum and heavy short interest creates a potentially explosive setup.
Liberty Defense announced that Cleveland Hopkins International Airport (CLE) will deploy two HEXWAVE systems for its Aviation Worker Screening program. Wadsworth Solutions is the prime contractor for installation, training, and support. This marks HEXWAVE's deployment at nine airports, indicating growing adoption in the aviation security market.
Raytheon, an RTX business, secured a five-year contract (with two option years) valued up to $24.4 billion for SM-6 interceptors from the U.S. Department of War. This multi-year award significantly boosts production of a combat-proven multi-mission missile, providing long-term revenue visibility for RTX's defense segment.
Rocket Lab announced a multi-year agreement for 20 Electron launches with Synspective, the largest commercial launch contract for Electron in the company's history. The deal brings total Synspective missions to 47 and pushes the launch backlog beyond 100 missions, but financial terms were not disclosed.
HII was awarded a U.S. Navy contract to build 10 ROMULUS unmanned surface vessels for the MUSV program, accelerating the Navy's shift to fleet-scale autonomous operations. The award leverages HII's Odyssey ACS autonomy suite and a distributed Gulf Coast production model, positioning the company for scalable unmanned vessel production. No contract value was disclosed, limiting immediate financial quantification.
Boeing was selected by the U.S. Navy for the F/A-XX program, a multi-billion-dollar contract to design, build, and deliver the Navy's 6th-generation fighter. This is Boeing's second 6th-gen fighter win following the Air Force's F-47 award in 2025, reinforcing its position in next-generation combat aircraft. The contract value is undisclosed, and program details remain classified.
HII's Newport News Shipbuilding division was awarded a $5.1 billion contract for the refueling and complex overhaul (RCOH) of the USS Harry S. Truman (CVN 75), with options that could increase the total to $5.18 billion. This is a large, multi-year contract that secures significant revenue visibility for HII's core shipbuilding business, though the stock has historically underperformed following positive news.
Leidos received a $242M contract modification from the Social Security Administration to exercise Option Year 5, add new requirements, and update pricing. This is a significant award for a key federal customer, though revenue impact cannot be precisely quantified without annual revenue data.
RTX's Raytheon unit received a five-year multi-year contract with two option years valued up to $20.7 billion from the Department of War to accelerate production of AMRAAM missiles. The contract supports annual production of at least 1,900 missiles and follows a landmark agreement announced earlier this year, nearly doubling production in 2025 vs 2024.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, received a $60.1M task order modification from the Department of Health and Human Services (NIAID) for FY26-27 operational support. This is a material contract award for a key government customer, reinforcing Leidos' position in federal health IT and research support services.
Rocket Lab's acquisition of Iridium cleared a key milestone with 99.6% of Iridium shares voted in favor (representing 81% of outstanding shares). The $54/share notional value deal (half cash, half stock) is expected to close by mid-2027, pending remaining regulatory approvals. This shareholder vote removes a major execution risk and moves the transformative combination closer to completion.
Leidos received a $149.8M contract modification from the National Science Foundation for science operations and maintenance support for the U.S. Antarctic Program. This is a large, sole-source-like modification for a long-running program, reinforcing Leidos' position as a key government services contractor.
Leidos received a $127 million contract extension from the U.S. Army to continue providing ARTEMIS airborne ISR operations through summer 2027, with two additional option years. The award supports Leidos' NorthStar 2030 strategy by expanding its Defense Tech and Mission & Digital Solutions portfolio.
Lockheed Martin received a $1.2B IDIQ contract from the U.S. Army to produce PrSM Increment 2, following a successful second flight test demonstrating moving maritime target engagement. The contract moves the missile from development into production, expanding Lockheed's long-range precision fires backlog.
Axon Enterprise amended its credit agreement to increase the revolving commitment from $300 million to $500 million, with $200 million in new commitments from existing lenders, concurrent with the closing of its $1.15 billion 0% convertible senior notes due 2031. The credit facility amendment and the convertible note issuance together provide Axon with substantial low-cost capital for general corporate purposes, including growth and M&A, while increasing total pro forma debt to approximately $2.75 billion.
Leonardo DRS announced it will provide the electric propulsion system for the Republic of Korea Navy's next-generation KDDX destroyer program. The contract value and timeline are not disclosed, but this represents a significant international naval defense win for the company.
No summary provided
Rocket Lab announced it has fully financed its pending $1.944 billion acquisition of Iridium Communications by completing a $1.944 billion ATM equity offering (29.3 million shares) and amending Iridium's existing $1.775 billion credit facility to permit the change of control, which also allowed the termination of the $3.6 billion bridge debt commitment. The acquisition is expected to close in mid-2027, pending regulatory approvals. This removes financing risk and de-levers the deal structure, but the massive equity dilution (~29.3M shares on a pre-deal base) is a material negative for existing common shareholders.
Rocket Lab fully funded its pending $1.944B Iridium acquisition by completing an ATM equity raise of ~$1.944B (29.3M shares) and securing a change-of-control amendment on Iridium's $1.775B term loan, allowing the debt to remain post-close. The $3.6B bridge facility was terminated, de-risking the capital structure. The deal is expected to close in mid-2027, pending regulatory approvals. This removes financing uncertainty but introduces significant dilution (~29.3M new shares) and a long timeline to close, with no financials disclosed to assess deal economics.
Axon Enterprise is issuing $1 billion of 0% convertible senior notes due 2031 (plus a $150 million over-allotment option) and simultaneously amending its credit facility to increase the revolving line from $300 million to $500 million. The company will use a portion of the proceeds to pay for capped call transactions intended to reduce dilution upon conversion, with the remainder for general corporate purposes including growth and M&A. This is a large-scale debt financing that significantly increases Axon's leverage (pro forma total debt of $2.75 billion) but provides substantial low-cost capital for a high-growth company with strong fundamentals (H1 2026 revenue up 34.5% YoY to $1.71B).
Rocket Lab completed a $1.944B ATM equity offering (29.3M shares) and secured a change-of-control amendment on Iridium's $1.775B credit facility, fully financing its pending acquisition of Iridium. The company also terminated the $3.6B bridge facility, de-risking the capital structure. The acquisition is expected to close in mid-2027 pending regulatory approvals.
T3 Defense subsidiary Rimon received a $1.3M purchase order from a leading Israeli defense prime for engineered power-generation systems supporting a European air-defense production line. This is Rimon's first order tied to European production activity, and the order has been added to Rimon's existing $2.1M backlog. Rimon's YTD revenue of $5.25M (as of July 31, 2026) already exceeds its full-year 2025 revenue of $4.6M, demonstrating accelerating demand.
T3 Defense Inc. filed an S-1 registration statement for the resale of up to 5,100,000 shares of common stock by selling stockholders (Esousa Group Holdings and others) — a contractual follow-up to the February 2026 Private Placement. The 5.1M shares represent approximately 64% of the currently outstanding shares, creating massive dilution overhang. The company is in severe financial distress with a going concern qualification, negative $19M stockholders' equity, a Nasdaq minimum equity deficiency notice, and $107.8M net loss in the first half of 2026. T3 receives no proceeds from the share sales and the underlying Common Warrants ($266.25 strike) are deeply out-of-the-money, making cash exercise unlikely.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings (LDOS), received a $113.7M modification to its NCI operational task order from the Department of Health and Human Services. This is a material contract action for a key federal customer, reinforcing Leidos's position in health IT and biomedical research services.
Leidos received a $159M contract modification from the Department of Homeland Security extending the period of performance to May 2028 and adding deployments. This is a significant award for a key federal customer, reinforcing Leidos's position in homeland security IT and services.
T3 Defense unwound its acquisition of a 60% stake in Project 35 Ltd., returning the 168,479 shares it issued and canceling a $1.25M note. Separately, the company disclosed that a massive 1.34M share issuance from S-8, Series B conversions, and warrant exercises ballooned its share count to 3,008,775 from 1,663,806 in just two weeks — an 81% dilution that dramatically reduces per-share value for existing holders.
A cluster of insider selling at Mercury Systems (MRCY) shows the CEO, CFO, and other top executives collectively sold ~$6.77M in open-market shares over a 7-day window. The CEO alone sold ~$20.5M across multiple days, including shares acquired via option exercises. While the dollar amount is modest relative to the $5.4B market cap (~0.38%), the breadth of C-suite participation and the CEO's large sales warrant attention, though insider sales are generally less predictive than buys.
Palantir CEO Alexander Karp executed a massive derivative exercise and open-market sale cluster on August 20, 2026, selling ~492,000 shares for approximately $85.8M. Director Alexander Moore also sold $609K worth of shares on August 17.
A mixed institutional cluster for AeroVironment (AVAV) in Q2 2026 shows 46 buyers accumulating $188.5M in new positions, led by Norges Bank ($78.1M new), BofA (doubled to $67.5M), and Millennium ($57.0M), while 35 sellers reduced holdings by $212.8M, dominated by passive funds like Geode (-$56.4M), UBS (-$55.9M), and Northern Trust (-$30.8M). The net selling of ~$24.3M and divergence between active buying and passive selling suggest uncertainty around near-term catalysts, with no insider buying corroboration.
Four KTOS insiders, including the CEO, President of the STC Division, and General Counsel, sold a total of $17.87M in shares over a one-week window. The CEO's $17.13M sale dominates the cluster, representing approximately 0.16% of the company's $11.4B market cap. While the dollar value is notable, the CEO's sale is the largest by far, and the cluster is entirely composed of open-market sales, which are generally weaker signals than buys per academic literature. The cross-filing actuarial verdicts show all combos as amplifiers, but the lack of any specific negative cross-filing context (e.g., late filing, restatement) means the standalone interpretation applies.
